Business ❯ Pharmaceutical Industry

Drug Manufacturers

Pricing Strategies Novo Nordisk Pricing Agreements Eli Lilly Pfizer AstraZeneca Market Dynamics Kenvue Market Competition Profit Margins Eli Lilly and Novo Nordisk Novo Nordisk and Eli Lilly Merck Cost Reduction Strategies Price Negotiations Price Negotiation Market Impact Market Regulations Discount Programs Price Agreements Purdue Pharma Market Regulation Negotiation Practices Negotiation Strategies Market Trends Amgen Rebates Healthcare Providers Market Agreements Research and Development Lilly Noro Nordisk Market History Patient Information Legal Settlements Negotiation Process IVF Drugs Profitability Regulatory Challenges Price Negotiation Lawsuits Medicare Part D Boehringer Ingelheim Bayer Collusion Abbvie and Genentech Government Relations Compliance EMD Serono Novo Nordisk Inc. Opioid Distributors Mifepristone Producers Bristol Myers Squibb Generic Drugs Negotiation Processes Merck KGaA Reformulation AbbVie Market Access Market Reactions Mifepristone Production Rebate Programs Pfizer Inc. Bristol Myers and Pfizer Danco Laboratories Market Strategies GSK PhRMA Insulin Manufacturers Distribution Companies Market Pricing Cost Management AbbVie and Genentech Product Quality Lobbying Johnson & Johnson Negotiations Compliance Standards Price Increases Regulatory Compliance Market Practices Weight Loss Drugs Legal Appeals GLP-1 Receptor Agonists Rebate Plans CEOs Weight-loss Drugs Medication Pricing Corporate Responsibility Revenue Impact Agreements Sanofi

HRSA Reworks 340B Pilot to Let Drugmakers Offer Voluntary Rebates

The agency says the redesign adds pre‑payment claim checks to block duplicate discounts and boost transaction visibility.

Medicare Opens $50 GLP-1 Bridge as Doctors Warn of Patient Surge

Supreme Court Rejects Drugmakers’ Appeals Over Medicare Price Talks

White House Projects $529 Billion in Savings From Trump’s MFN Drug Pricing Plan

AbbVie, Genentech Join TrumpRx With Deep Discounts on Humira and Xofluza

Drug-Cost Anxiety Hits New High in KFF Poll as TrumpRx Sees Limited Reach

Trump Presses Congress to Lock In Drug Pricing Deals as He Showcases TrumpRx at State of the Union

Democratic Report Puts TrumpRx Under Fresh Scrutiny as Analyses Question Real-World Savings

Lawmakers Seek Transparency as TrumpRx Faces Questions on Who Saves

TrumpRx Debuts With 43 Discounted Brand Drugs as Analyses Flag Cheaper Generics and Limits

TrumpRx Launches, Offering Discounted Brand‑Name Drugs Through U.S. Portal

GLP-1 Weight-Loss Push Intensifies as Novo Leads Ads and Wegovy Pill Drives Telehealth Uptake

AbbVie Strikes Trump Drug-Pricing Deal, Pledges $100 Billion, Wins 3-Year Tariff Reprieve

Oregon Sues Insulin Makers and PBMs, Alleging $900 Million Pricing Scheme

Indiana Sues Eli Lilly, Alleging Scheme to Inflate Insulin Prices

Drugmakers to Lift 2026 U.S. List Prices on 350 Branded Medicines

CMS Unveils Voluntary BALANCE Program to Lower GLP-1 Costs for Medicare and Medicaid

White House Adds 9 Pharma Deals, Extending Drug-Price Pacts to 14 Manufacturers

Trump Adds Nine Pharma Giants to Drug Pricing Deals, Reaching 14 Signatories as TrumpRx Nears Launch

Medicare’s First Negotiated Drug Prices Take Effect Jan. 1, Cutting 2026 Costs